MapLight Therapeutics Updates Timing for ZEPHYR and IRIS Clinical Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy MPLT?
MapLight Therapeutics announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MPLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.610
Low
28.00
Averages
31.00
High
34.00
Current: 22.610
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
MapLight Therapeutics Reports Q4 Financial Results
- Earnings Report: MapLight Therapeutics reported a GAAP EPS of -$2.47 for Q4, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Reserves: As of December 31, 2025, the company had $453.1 million in cash, cash equivalents, and investments, suggesting a reasonable liquidity cushion for ongoing operations.
- Funding Outlook: Based on current operational plans and assumptions, the company expects its existing cash and investments to be sufficient to fund operations through 2027, reflecting management's confidence in future financial stability.
- Historical Financial Data: The historical earnings data for MapLight Therapeutics provides context on the company's past performance, aiding investors in assessing its long-term growth potential and associated risks.
See More
Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47
- Financial Performance: Maplight reported a net loss of $79.5 million for Q4.
- Earnings Per Share: The company's earnings per share (EPS) for the quarter was -$2.47.
See More
Maplight and CVRx Executives Increase Stock Holdings
- Maplight Purchase: George Pavlov of Maplight Therapeutics made a $441,168 purchase of 25,000 shares of MPLT at $17.65 each on Friday, marking his first buy in the past twelve months, indicating confidence in the company's future prospects.
- Market Performance: On Monday, Maplight Therapeutics' stock traded down approximately 1.4%, and while Pavlov's purchase may not have immediately boosted the stock price, his long-term investment intentions could influence market sentiment.
- CVRx Purchase: Mudit K. Jain also bought $297,592 worth of CVRx, acquiring 46,800 shares at $6.36 each on Friday, which is his third purchase in the past twelve months, reflecting his ongoing optimism about CVRx.
- Stock Fluctuation: CVRx's stock rose about 12.1% on Monday, reaching a high of $7.22, with Jain's investment up approximately 13.5% at the peak, showcasing a positive market reaction to CVRx.
See More
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
See More
MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
- Clinical Trial Progress: MapLight Therapeutics' ZEPHYR trial is accelerating enrollment, with topline results for 300 schizophrenia patients now expected in Q3 2026, showcasing the company's efficient execution under high-quality standards.
- IRIS Trial Update: The IRIS trial has completed enrollment, with topline results for approximately 160 autism patients also anticipated in Q3 2026, further enhancing the company's research capabilities in central nervous system disorders.
- Strategic Commitment: CEO Chris Kroeger emphasized that the rapid enrollment pace not only narrows timing guidance but also demonstrates the company's commitment to advancing its programs, potentially boosting investor confidence and attracting more funding support.
- Market Potential: With a focus on developing drugs for mental health disorders, MapLight is positioned to fill the market gap for specific therapies as clinical trials progress, driving future business growth.
See More
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
MapLight Therapeutics Reports Q4 Financial Results
- Earnings Report: MapLight Therapeutics reported a GAAP EPS of -$2.47 for Q4, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Reserves: As of December 31, 2025, the company had $453.1 million in cash, cash equivalents, and investments, suggesting a reasonable liquidity cushion for ongoing operations.
- Funding Outlook: Based on current operational plans and assumptions, the company expects its existing cash and investments to be sufficient to fund operations through 2027, reflecting management's confidence in future financial stability.
- Historical Financial Data: The historical earnings data for MapLight Therapeutics provides context on the company's past performance, aiding investors in assessing its long-term growth potential and associated risks.
See More
Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47
- Financial Performance: Maplight reported a net loss of $79.5 million for Q4.
- Earnings Per Share: The company's earnings per share (EPS) for the quarter was -$2.47.
See More
Maplight and CVRx Executives Increase Stock Holdings
- Maplight Purchase: George Pavlov of Maplight Therapeutics made a $441,168 purchase of 25,000 shares of MPLT at $17.65 each on Friday, marking his first buy in the past twelve months, indicating confidence in the company's future prospects.
- Market Performance: On Monday, Maplight Therapeutics' stock traded down approximately 1.4%, and while Pavlov's purchase may not have immediately boosted the stock price, his long-term investment intentions could influence market sentiment.
- CVRx Purchase: Mudit K. Jain also bought $297,592 worth of CVRx, acquiring 46,800 shares at $6.36 each on Friday, which is his third purchase in the past twelve months, reflecting his ongoing optimism about CVRx.
- Stock Fluctuation: CVRx's stock rose about 12.1% on Monday, reaching a high of $7.22, with Jain's investment up approximately 13.5% at the peak, showcasing a positive market reaction to CVRx.
See More
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
See More
MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
- Clinical Trial Progress: MapLight Therapeutics' ZEPHYR trial is accelerating enrollment, with topline results for 300 schizophrenia patients now expected in Q3 2026, showcasing the company's efficient execution under high-quality standards.
- IRIS Trial Update: The IRIS trial has completed enrollment, with topline results for approximately 160 autism patients also anticipated in Q3 2026, further enhancing the company's research capabilities in central nervous system disorders.
- Strategic Commitment: CEO Chris Kroeger emphasized that the rapid enrollment pace not only narrows timing guidance but also demonstrates the company's commitment to advancing its programs, potentially boosting investor confidence and attracting more funding support.
- Market Potential: With a focus on developing drugs for mental health disorders, MapLight is positioned to fill the market gap for specific therapies as clinical trials progress, driving future business growth.
See More
